A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Flutafuranol F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2018, according to ClinicalTrials.gov record.
- 29 Mar 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018, according to ClinicalTrials.gov record.